Artificial Intelligence

Banuba's new AI Talking Photo API promises to revolutionize video creation, but the rise of lifelike digital avatars also fuels a critical ethical debate.

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Infrastructure software giant posts 11% revenue growth, outlines a bullish 2026 forecast, and doubles down on AI with key acquisitions.

A new partnership brings AI to customs, promising to help U.S. importers reclaim millions in overpaid duties and navigate volatile global trade.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

Robert Herjavec invests in AI firm Lovelytics, betting on the critical need for data infrastructure and aiming to scale the top Databricks partner.

As a 24-year CEO era ends, McCoy Global bets on an internal tech architect to lead its future in automated well construction and maintain growth.

As Matricelf presents its breakthrough therapy at a major summit, the company moves closer to human trials, offering new hope for paralysis patients.

Romania's new 1,500km quantum network, powered by IonQ, marks a major step in Europe's race to secure critical data against future cyber threats.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

Former USAA CEO Wayne Peacock joins Cotality's board, signaling a strategic push to lead the AI-driven property data and insurance analytics market.

A new partnership aims to capitalize on surging defense spending and supply chain shifts, signaling a new era for specialized private equity investing.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

Facing slow auto OEM cycles, Arbe Robotics names a new CEO and targets defense, robotaxis, and China to accelerate revenue from its high-res radar tech.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

Vistra posts record 2025 results and a bullish 2026 forecast, fueled by major acquisitions and landmark nuclear power deals with tech titans AWS and Meta.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.